CombiMatrix (CBMX) to Present Data from NIPT in Chromosomal Aneuploidies, Microdeletion Syndromes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
New Data From CombiMatrix Study Support Follow-Up Diagnostic Testing to Confirm Positive Results From Non-Invasive Prenatal Testing
October 9, 2015 6:00 AM EDTIRVINE, Calif., Oct. 9, 2015 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ: CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces the presentation of data supporting the value of follow-up diagnostic testing to confirm or rule out positive results for common chromosomal aneuploidies and microdeletion syndromes detected by non-invasive prenatal testing (NIPT). Data from the unpublished study conducted by CombiMatrix were presented by Trilochan Sahoo, M.D., FACMG, CombiMatrix's Vice President of Clinical Affairs and Director of Cytogenetics, in a presentation late yesterday at the... More
New Data From CombiMatrix Study Support Follow-Up Diagnostic Testing to Confirm Positive Results From Non-Invasive Prenatal Testing
October 9, 2015 6:00 AM EDTIRVINE, Calif., Oct. 9, 2015 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ: CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces the presentation of data supporting the value of follow-up diagnostic testing to confirm or rule out positive results for common chromosomal aneuploidies and microdeletion syndromes detected by non-invasive prenatal testing (NIPT). Data from the unpublished study conducted by CombiMatrix were presented by Trilochan Sahoo, M.D., FACMG, CombiMatrix's Vice President of Clinical Affairs and Director of Cytogenetics, in a presentation late yesterday at the... More
